Blood Sparing Efficacy of Oral Tranexamic Acid in Primary Total Knee Arthroplasty: A Randomized Controlled Trial
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
purpose: Tranexamic acid (TXA) is effective in reducing blood loss in primary total knee replacement. Almost all studies used an intravenous form or a topical form. The aim of this study was to assess the blood sparing efficacy and the safety of oral TXA.Materials and Methods: All patients with primary total knee replacement performed in our institute from January 2015 to October 2015 were eligible. Oral TXA group was given 1 g oral TXA 2 hours before induction of anesthesia and 6 hours and 12 hours postoperatively. The control group was not given TXA.results: There were 94 cases in the oral TXA group and 95 cases in the control group. There was no difference in the baseline characteristics. The oral TXA group had a significantly lower hemoglobin drop (1.7 g/dL vs. 2.5 g/dL), lower drain output (154 mL vs. 203 mL), lower hidden blood loss (244 mL vs. 423 mL) and lower total blood loss (398 mL vs. 626 mL). There was no difference in transfusion rate (1.1% vs. 3.2%) and thromboembolic complication. There was no infection or mortality in both groups.conclusions: Oral TXA is effective in reducing blood loss in primary total knee replacement. It is a safe alternative to the intravenous or topical form.
Abstract
purpose: Tranexamic acid (TXA) is effective in reducing blood loss in primary total knee replacement. Almost all studies used an intravenous form or a topical form. The aim of this study was to assess the blood sparing efficacy and the safety of oral TXA.Materials and Methods: All patients with primary total knee replacement performed in our institute from January 2015 to October 2015 were eligible. Oral TXA group was given 1 g oral TXA 2 hours before induction of anesthesia and 6 hours and 12 hours postoperatively. The control group was not given TXA.results: There were 94 cases in the oral TXA group and 95 cases in the control group. There was no difference in the baseline characteristics. The oral TXA group had a significantly lower hemoglobin drop (1.7 g/dL vs. 2.5 g/dL), lower drain output (154 mL vs. 203 mL), lower hidden blood loss (244 mL vs. 423 mL) and lower total blood loss (398 mL vs. 626 mL). There was no difference in transfusion rate (1.1% vs. 3.2%) and thromboembolic complication. There was no infection or mortality in both groups.conclusions: Oral TXA is effective in reducing blood loss in primary total knee replacement. It is a safe alternative to the intravenous or topical form.
참고문헌 (30)
- Yang ZG, "Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty : a meta-analysis", J Bone Joint Surg Am, 94, pp.1153~1159 (2012)
- Alshryda S, "A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement", Bone Joint J, 96, pp.1005~1015 (2014)
- Zhang H, "The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty : a meta-analysis", Knee Surg Sports Traumatol Arthrosc, 20, pp.1742~1752 (2012)
- Poeran J, "Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety", BMJ, 349, pp.g4829~ (2014)
- Panteli M, "Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis", Knee, 20, pp.300~309 (2013)
- Good L, "Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement", Br J Anaesth, 90, pp.596~599 (2003)
- Molloy DO, "Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement : a prospective, randomised controlled trial", J Bone Joint Surg Br, 89, pp.306~309 (2007)
- Alvarez JC, "Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied", Transfusion, 48, pp.519~525 (2008)
- Aguilera X, "Efficacy and safety of fibrin glue and tranexamic acid to prevent postoperative blood loss in total knee arthroplasty : a randomized controlled clinical trial", J Bone Joint Surg Am, 95, pp.2001~2007 (2013)
- Wong J, "Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty : a randomized, controlled trial", J Bone Joint Surg Am, 92, pp.2503~2513 (2010)
- Roy SP, "Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty", Knee Surg Sports Traumatol Arthrosc, 20, pp.2494~2501 (2012)
- Konig G, "Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty", J Arthroplasty, 28, pp.1473~1476 (2013)
- Aguilera X, "Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty : a multicenter, randomized, controlled trial", Arch Orthop Trauma Surg, 135, pp.1017~1025 (2015)
- Gomez-Barrena E, "Topical intraarticular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement : a doubleblind, randomized, controlled, noninferiority clinical trial", J Bone Joint Surg Am, 96, pp.1937~1944 (2014)
- Duncan CM, "Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty", J Arthroplasty, 30, pp.272~276 (2015)
- Gillette BP, "Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty", Clin Orthop Relat Res, 471, pp.150~154 (2013)
- Lucas-Polomeni MM, "A case of anaphylactic shock with tranexamique acid(Exacyl)", Ann Fr Anesth Reanim, 23, pp.607~609 (2004)
- Klak M, "Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis", Scand J Infect Dis, 42, pp.351~358 (2010)
- Bradshaw AR, "Oral tranexamic acid reduces blood loss in total knee replacement arthroplasty", Curr Orthop Prac, 23, pp.209~212 (2012)
- Zohar E, "The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement", Anesth Analg, 99, pp.1679~1683 (2004)
- Fillingham YA, "The James A. Rand Young Investigator’s Award: a randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost?", J Arthroplasty, 31(9 Suppl), pp.26~30 (2016)
- Alipour M, "Effectiveness of oral tranexamic acid administration on blood loss after knee artroplasty : a randomized clinical trial", Transfus Apher Sci, 49, pp.574~577 (2013)
- McGrath S, "Oral tranexamic acid in hip and knee arthroplasty : a prospective cohort study", Open J Orthop, 4, pp.215~220 (2014)
- Lee QJ, "Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty", J Arthroplasty, 32, pp.139~142 (2017)
- Irwin A, "Oral versus intravenous tranexamic acid in enhancedrecovery primary total hip and knee replacement : results of 3000 procedures", Bone Joint J, 95, pp.1556~1561 (2013)
- Nadler SB, "Prediction of blood volume in normal human adults", Surgery, 51, pp.224~232 (1962)
- Pilbrant A, "Pharmacokinetics and bioavailability of tranexamic acid", Eur J Clin Pharmacol, 20, pp.65~72 (1981)
- Blanie A, "Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study", Thromb Res, 131, pp.e6~e11 (2013)
- Kaku Y, "Generalized fixed drug eruption induced by tranexamic acid", Eur J Dermatol, 24, pp.408~409 (2014)
- Imbesi S, "Hypersensitivity to tranexamic acid : a wide spectrum of adverse reactions", Pharm World Sci, 32, pp.416~419 (2010)